Esin Aysel Kandemir

8PUBLICATIONS
17CO-AUTHORS
ChemotherapyPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 20, 2025
A research gap in oncology pharmacy: Participation of pharmacists in the multidisciplinary tumor board (MTB) meetings as an important component of effective and safe cancer treatment.

Esin Aysel Kandemir

|May 29, 2025
Adherence to Multidisciplinary Tumor Board Recommendations and Its Association with Survival: A Retrospective Observational Study of Colorectal Cancer Patients.

Esin Aysel Kandemir, Julia Roeper, Heiner Zimmermann

|Apr 28, 2023
Off-label use of immune checkpoint inhibitors for the treatment of solid tumors: analysis of a nationwide patient sample.

Esin Aysel Kandemir, Irem Karaomerlioglu, Ibrahim Muaz Yaradilmis

|Jul 06, 2022
Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021.

Esin Aysel Kandemir

|Apr 06, 2022
International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions.

Andrew Walker, Alexandre Chan, Constanza Cortés Labra

|Sep 24, 2021
Oncologists' attitudes towards prophylaxis of cancer associated venous thromboembolism: A prospective, descriptive study.

Esin Aysel Kandemir, Aygin Bayraktar-Ekincioglu, Saadettin Kilickap

Pageof 2

Frequent Collaborators

3 joint publications

Aygin Bayraktar-Ekincioglu

2 joint publications

Karunrat Tewthanom

2 joint publications

Elif Aras-Atik

1 joint publications

Saadettin Kilickap